Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2018 1
2019 1
2020 2
2021 1
2022 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Abandoning the Notion of Non-Small Cell Lung Cancer.
Relli V, Trerotola M, Guerra E, Alberti S. Relli V, et al. Trends Mol Med. 2019 Jul;25(7):585-594. doi: 10.1016/j.molmed.2019.04.012. Epub 2019 May 30. Trends Mol Med. 2019. PMID: 31155338 Review.
Epigenetic inheritance and the missing heritability.
Trerotola M, Relli V, Simeone P, Alberti S. Trerotola M, et al. Among authors: relli v. Hum Genomics. 2015 Jul 28;9(1):17. doi: 10.1186/s40246-015-0041-3. Hum Genomics. 2015. PMID: 26216216 Free PMC article. Review.
3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability.
Guerra E, Trerotola M, Relli V, Lattanzio R, Tripaldi R, Ceci M, Boujnah K, Pantalone L, Sacchetti A, Havas KM, Simeone P, Travali N, Querzoli P, Pedriali M, Roversi P, Iezzi M, Tinari N, Antolini L, Alberti S. Guerra E, et al. Among authors: relli v. Mol Cancer Ther. 2023 Jun 1;22(6):790-804. doi: 10.1158/1535-7163.MCT-22-0352. Mol Cancer Ther. 2023. PMID: 36921314
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies.
Brandi G, Relli V, Deserti M, Palloni A, Indio V, Astolfi A, Serravalle S, Mattiaccio A, Vasuri F, Malvi D, Deiana C, Pantaleo MA, Cescon M, Rizzo A, Katoh M, Tavolari S. Brandi G, et al. Among authors: relli v. Sci Rep. 2024 Feb 7;14(1):3136. doi: 10.1038/s41598-024-52991-8. Sci Rep. 2024. PMID: 38326380 Free PMC article.
Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer.
Guerra E, Trerotola M, Relli V, Lattanzio R, Tripaldi R, Vacca G, Ceci M, Boujnah K, Garbo V, Moschella A, Zappacosta R, Simeone P, de Lange R, Weidle UH, Rotelli MT, Picciariello A, Depalo R, Querzoli P, Pedriali M, Bianchini E, Angelucci D, Pizzicannella G, Di Loreto C, Piantelli M, Antolini L, Sun XF, Altomare DF, Alberti S. Guerra E, et al. Among authors: relli v. Neoplasia. 2021 Sep;23(9):898-911. doi: 10.1016/j.neo.2021.07.002. Epub 2021 Jul 25. Neoplasia. 2021. PMID: 34320447 Free PMC article.
Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion.
Guerra E, Relli V, Ceci M, Tripaldi R, Simeone P, Aloisi AL, Pantalone L, La Sorda R, Lattanzio R, Sacchetti A, Havas K, Guarnieri S, Vergara D, Fournier I, Salzet M, Tinari N, Piantelli M, Trerotola M, Alberti S. Guerra E, et al. Among authors: relli v. Oncogene. 2022 Mar;41(12):1795-1808. doi: 10.1038/s41388-022-02220-1. Epub 2022 Feb 7. Oncogene. 2022. PMID: 35132180
Trop-2 is a determinant of breast cancer survival.
Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli P, Pedriali M, Piantelli M, Biganzoli E, Alberti S. Ambrogi F, et al. Among authors: relli v. PLoS One. 2014 May 13;9(5):e96993. doi: 10.1371/journal.pone.0096993. eCollection 2014. PLoS One. 2014. PMID: 24824621 Free PMC article.
14 results